CHAPTER 2: KEY FIGURES IN 2025
Administrative aspects
Financial information
The Agency’s total revenue in 2025 was EUR 607.56 million, a 21 % increase compared to EUR 502.59 million in 2024.
Remuneration to national competent authorities
NCAs in the EU Member States receive a share of EMA’s revenue from fees for the assessments they carry out on behalf of the Agency. In 2025, EMA paid a total of EUR 234.67 million to the NCAs, a 33 % increase over 2024. This figure includes payments for pharmacovigilance procedures, including the assessment of PSURs, PASS protocols and study results, and of pharmacovigilance-related referrals.
Implementation of the new fee regulation
Following adoption of a revised regulation on fees and charges payable to EMA (Regulation (EU) 2024/568), EMA implemented the new regulation as of 1 January 2025.
The regulation aims to ensure the sustainability of the EMRN, providing a sound financial basis to support its operations as well as the objectives outlined in the EMANS.
Agency staff
As of December 2025, the Agency had 1,035 staff members: 676 women and 359 men.